Abstract: A lumen stent (100) includes a tubular stent and an imaging marker; the tubular stent includes a main body stent (11); the imaging marker includes a first marker (211) provided on the main body stent (11); and the shape of the first marker (211) provided on the main body stent (11) is asymmetrical at least along a longitudinal axis. A non-axisymmetric imaging marker is provided on the main body stent (11), and the position and orientation of the lumen stent (100) implanted in the body can be accurately and clearly displayed through the imaging marker, to allow the operator to observe and quickly judge and timely adjust, thereby shortening the operation time of the endovascular treatment and reducing the difficulty of the operation.

Abstract: An ionizable lipid based on cyclohexanediamine and a lipid nanoparticle, and a preparation method therefor and use thereof. The ionizable lipid based on cyclohexanediamine is a compound represented by formula (a), wherein n is independently selected from natural numbers of 0-8; R1, R2, R3 and R4 are independently selected from C8-C24 alkyl, C8-C24 alkyl substituted by a substituent group, C8-C24 alkenyl, C8-C24 alkenyl substituted by a substituent group, and C8-C24 alkynyl and C8-C24 alkynyl substituted by a substituent group. The lipid nanoparticle formed by the ionizable lipid based on cyclohexanediamine has the advantages of biodegradability, high in-vivo and in-vitro transfection efficiency, and the like, and has a good clinical application prospect.

Abstract: An ionizable lipid based on endogenous dicarboxylic acid as well as a preparation method and use thereof. The ionizable lipid based on endogenous dicarboxylic acid is a compound represented by Formula (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate thereof; wherein, X is selected from — Y is selected from —O— and —NH—; R is selected from C6-C20 alkyl, C6-C20 alkyl substituted by a substituent group, C6-C20 alkenyl, C6-C20 alkenyl substituted by a substituent group, C6-C20 alkynyl, and C6-C20 alkynyl substituted by a substituent group; n is an integer of 1-8.

Abstract: A lumen stent (100) and an implant are provided. The lumen stent includes a tubular body (11), an inner branch (12) and an outer branch (13) which are respectively communicated with the tubular body (11). The tubular body (11) includes a first body segment (111), a tapered segment (112) and a second body segment (113) which are connected in sequence. The tapered segment (112) is provided with an outer branch window (110b) and an inner branch window (110a). The proximal end of the outer branch (13) is connected to the outer branch window (110b). The distal end of the inner branch (12) is connected to the inner branch window (110a). The area of the inner branch window (110a) is larger than that of the outer branch window (110b).

Abstract: A lumen stent (100) and an implant are provided. The lumen stent includes a tubular body (11), an inner branch (12) and an outer branch (13) which are respectively communicated with the tubular body (11). The tubular body (11) includes a first body segment (111), a tapered segment (112) and a second body segment (113) which are connected in sequence. The tapered segment (112) is provided with an outer branch window (110b) and an inner branch window (110a). The proximal end of the outer branch (13) is connected to the outer branch window (110b). The distal end of the inner branch (12) is connected to the inner branch window (110a). The area of the inner branch window (110a) is larger than that of the outer branch window (110b).

Abstract: A luminal stent (100) is provided, including a tubular main body (11) and a semi-releasing device (20) connected to the tubular main body (11). The tubular main body (11) includes a binding area (112) and a non-binding area (111) distributed in a circumferential direction. The semi-releasing device (20) includes a limiting rod (21) located outside the tubular main body (11), and binding lines (22) and limiting fasteners (23) arranged on the tubular main body (11). The binding lines (22) are arranged in the binding area (112). The binding lines (22) each include a fixed end (22a), a binding portion (22b) and a locking portion (22c) which are connected to one another. The fixed ends (22a) are fixedly connected to the tubular main body (11). Both the locking portions (22c) and the limiting fasteners (23) are detachably connected to the limiting rod (21).

Abstract: A PEGylated ICD inducer-IDO inhibitor nanoconjugate and a preparation method and use thereof. The nanoconjugate has a structural formula as follows: where R is H or with a weight-average molecular weight of 1000-5000. For the PEGylated ICD inducer-IDO inhibitor nanoconjugate provided in an aqueous medium, the PEGylated drug conjugate can self-assemble into a drug-based nanoconjugate, which can not only reduce non-specific accumulation in MPS-related organs, but also improve the passive targeting capability to solid tumors through the enhanced permeability and retention effect, thereby increasing the therapeutic index.

Abstract: A lumen stent (100) and an implant are provided. The lumen stent includes a tubular body (11), an inner branch (12) and an outer branch (13) which are respectively communicated with the tubular body (11). The tubular body (11) includes a first body segment (111), a tapered segment (112) and a second body segment (113) which are connected in sequence. The tapered segment (112) is provided with an outer branch window (110b) and an inner branch window (110a). The proximal end of the outer branch (13) is connected to the outer branch window (110b). The distal end of the inner branch (12) is connected to the inner branch window (110a). The area of the inner branch window (110a) is larger than that of the outer branch window (110b).